Yew W W, Tam C M, Chan C Y, Li M S, Cheng A F
Tuberculosis & Chest Unit, Grantham Hospital, Aberdeen, Hong Kong.
Int J Clin Pharmacol Res. 1993;13(2):65-8.
Twenty clinical isolates of Mycobacterium avium-intracellulare were tested with amikacin and sulphamethoxazole for in-vitro susceptibilities. The MICs and MBCs of the former drug ranged from 8 to > 64 mg/L (median MIC: 64 mg/L, median MBC: > 64 mg/L). The MICs and MBCs of the latter drug were found to be > 256 mg/L. Each of eight patients with invasive pulmonary disease due to these organisms was treated with amikacin for six months and with cotrimoxazole (sulphamethoxazole-trimethoprim) for one year. Only one patient had sustained bacteriological conversion. Three patients showed a transient reduction of bacillary load during the period of amikacin administration. The rest all failed to show response. Thus sulphamethoxazole was found to have no activity against Mycobacterium avium-intracellulare, and amikacin has doubtful activity when used alone in treatment of M. avium-intracellulare infection.
对20株鸟分枝杆菌-胞内分枝杆菌临床分离株进行了阿米卡星和磺胺甲恶唑的体外药敏试验。前一种药物的最低抑菌浓度（MIC）和最低杀菌浓度（MBC）范围为8至>64mg/L（中位MIC：64mg/L，中位MBC：>64mg/L）。后一种药物的MIC和MBC均>256mg/L。8例因这些病原体导致侵袭性肺部疾病的患者，均接受了6个月的阿米卡星治疗和1年的复方新诺明（磺胺甲恶唑-甲氧苄啶）治疗。只有1例患者实现了持续的细菌学转阴。3例患者在使用阿米卡星期间细菌载量出现短暂下降。其余患者均未显示出反应。因此，发现磺胺甲恶唑对鸟分枝杆菌-胞内分枝杆菌无活性，而阿米卡星单独用于治疗鸟分枝杆菌-胞内分枝杆菌感染时活性存疑。
